-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 15, 2021, Bright Peak Therapeutics of the United States announced that Livzonumab, a subsidiary of Livzon Group, has signed a research cooperation and licensing agreement with Bright Peak Therapeutics (hereinafter referred to as BPTx) in the United States
.
Livzonumab has licensed the recombinant humanized anti-PD-1 monoclonal antibody for injection (LZM009) with independent intellectual property rights (LZM009) to BPTx for a paid and non-exclusive license for the development of new PD-1 targeted immune cytokines (PD-1 ICs) , And authorized LZM009 to BPTx for the development and commercialization of PD-1 ICs drugs in regions other than Greater China
According to the terms of the license agreement, BPTx will have the right to develop, manufacture and commercialize PD-1 ICs worldwide, and Livzon will obtain exclusive preferential negotiation rights in Greater China
.
Livzon will receive a one-time cash down payment from BPTx, and later will receive development and registration milestone fees, as well as a sales commission on global net sales
LZM009 is a human IgG4 monoclonal antibody that binds to PD-1 molecules on the surface of T cells, blocks the PD-1/PD-1 ligand (PD-L1) pathway, and reactivates T cells to kill cancer cells
.
LZM009 has been approved to conduct clinical trials in China and the United States and has completed clinical dose exploration trials
It is understood that BPTx is a biotechnology company that develops next-generation cytokine immunotherapy, dedicated to exerting the powerful biological activity of cytokines while significantly improving their safety
.
Through BPTx’s unique chemical protein synthesis and engineering platform, cytokines can be precisely designed to fine-tune receptor binding and optimize efficacy.
Fredrik Wiklund, President and CEO of BPTx, said: “We are very pleased to obtain the license of Livzon’s anti-PD-1 monoclonal antibody LZM009 to extensively develop PD-1 targeted immune cytokines through the use of our proprietary platform technology
.
In recent years, PD -1 inhibitors have changed the treatment of cancer
Dr.
Bertolt Kreft, Chief Scientific Officer of BPTx, said: "We are very pleased to apply the technical advantages and versatility of the synthetic protein engineering platform to clinical-stage antibodies.
